Amlogenyx

Amlogenyx Inc., a subsidiary of Ultragenyx Pharmaceutical, Inc., is focused on researching and developing novel gene therapies for Alzheimer's disease and other amyloid diseases. Their lead product candidate is a protease designed to break down Aβ42, a protein believed to be responsible for Alzheimer's debilitating effects.

Buy Funded Startups lists

Funding Round: Seed

Funding Amount: $14M

Date: 02-Aug-2024

Investors: GordonMD ® Global Investments LP, Ultragenyx

Markets: Biotechnology, Gene Therapy, Pharmaceuticals, Genetics, Therapeutics

HQ: Somerville, Massachusetts, United States

Founded: 2023

Website: https://www.amlogenyx.com

LinkedIn:

Twitter:

Instagram: